WiDr

Carcinogenesis and tumourigenicity studies and anti-tumour testing

Although originally described as a colon adenocarcinoma line established from a 78 year old female, DNA fingerprinting has shown this line to be a derivative of HT-29. HT29 was isolated from a primary colon adenocarcinoma in a 44 year old Caucasian female. The cells produce carcinoembryonic antigen and are tumorigenic in xenogeneic animals. They have been used in studies of anti-tumour agents.

Human colon adenocarcinoma

STR-PCR Data: Amelogenin: X
CSF1PO: 11,12
D13S317: 11,12
D16S539: 11,12
D5S818: 11,12
D7S820: 10
THO1: 6,9
TPOX: 8,9
vWA: 17,19 STR-PCR Data: Amelogenin: X
CSF1PO: 11,12
D13S317: 11,1

EMEM (EBSS) + 2mM Glutamine + 1% Non Essential Amino Acids (NEAA) + 10% Foetal Bovine Serum (FBS).

Split sub-confluent cultures (70-80%) 1:5 to 1:10 i.e. seeding at 1-2x10,000 cells/cm² using 0.25% trypsin or trypsin/EDTA; 5% CO₂; 37°C.

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). No licensing agreement is required when either this cell line or the DNA extracted from it are used for internal research purposes only. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to culturecollections@ukhsa.gov.uk.